Triplet Delays Breast Cancer Progression in First-Line Maintenance Setting

(MedPage Today) — SAN ANTONIO — Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab and pertuzumab (Perjeta) significantly improved progression-free survival (PFS) in patients with HER2-positive metastatic breast cancer…

Source link : https://www.medpagetoday.com/meetingcoverage/sabcs/118958

Author :

Publish date : 2025-12-11 17:19:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31

Triplet Delays Breast Cancer Progression in First-Line Maintenance Setting

Wes Streeting confirms public inquiry into Teesside NHS trust

Disney and OpenAI have made a surprise deal – what happens next?

Related Posts

FDA Approves New Type of Antibiotic for Gonorrhea, First in Decades

RFK Jr.’s Former Group Urges FDA to Revoke COVID Vax Licenses

Florida Sues Medical Groups Over Youth Gender-Affirming Care

Low Prenatal Vitamin D Linked to Early Cavities in Children

RFK Jr.’s Viral Pull-Ups; Docs Denounce ACIP’s Hep B Vote; ‘Don’t Pee!’

ADC Post-Endocrine Therapy Misses Mark in Advanced Breast Cancer Trial

FDA Approves New Type of Antibiotic for Gonorrhea, First in Decades

RFK Jr.’s Former Group Urges FDA to Revoke COVID Vax Licenses

Florida Sues Medical Groups Over Youth Gender-Affirming Care

Low Prenatal Vitamin D Linked to Early Cavities in Children

RFK Jr.’s Viral Pull-Ups; Docs Denounce ACIP’s Hep B Vote; ‘Don’t Pee!’

ADC Post-Endocrine Therapy Misses Mark in Advanced Breast Cancer Trial

FDA Proposes Allowing New Sunscreen Ingredient

FDA OKs First At-Home Brain Stim Device for Depression

Categories

Archives